Trial reportThe Journal of clinical endocrinology and metabolism2011
Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
Trial report in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Quality appraisal of clinical practice guidelines for the evaluation and management of primary hyperparathyroidism.Endocrine · 2024Pooled it
- Pooled it
- Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.European journal of endocrinology · 2015Trial
- Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism.Endocrine journal · 2025Article
- Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.Endocrine reviews · 2025Review
- Management of surgical diseases of Primary Hyperparathyroidism: indications of the United Italian Society of Endocrine Surgery (SIUEC).Updates in surgery · 2024Review
- Pediatric Neuroendocrine Neoplasia of the Parathyroid Glands: Delving into Primary Hyperparathyroidism.Biomedicines · 2023Review
- Parathyroid Retrospective Analysis of Neoplasms Incidence (pTRANI Study): An Italian Multicenter Study on Parathyroid Carcinoma and Atypical Parathyroid Tumour.Journal of clinical medicine · 2023Article
- Primary hyperparathyroidism in the geriatric population: A case report and mini literature review.Clinical case reports · 2022Article
- Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic.Clinical therapeutics · 2021Review
- Biochemical bone turnover markers in hormonal disorders in adults: a narrative review.Journal of endocrinological investigation · 2020Review
- Review
- Familial hypocalciuric hypercalcemia and related disorders.Best practice & research. Clinical endocrinology & metabolism · 2018Review
- Successful use of cinacalcet to treat parathyroid-related hypercalcemia in two pediatric patients.Endocrinology, diabetes & metabolism case reports · 2018Article
- Calcimimetic Use in Familial Hypocalciuric Hypercalcemia-A Perspective in Endocrinology.The Journal of clinical endocrinology and metabolism · 2017Review
- Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review.Frontiers in endocrinology · 2017Review
- Hypercalcemia in pregnancy - a multifaceted challenge: case reports and literature review.Clinical case reports · 2016Article
- Update on parathyroid carcinoma.Journal of endocrinological investigation · 2016Review
- The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future.Frontiers in physiology · 2016Review
- Primary Hyperparathyroidism.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
contextPrimary hyperparathyroidism (PHPT) is characterized by elevated serum calcium (Ca) and increased PTH concentrations.
objectiveThe objective of the investigation was to establish the efficacy of cinacalcet in reducing serum Ca in patients with PHPT across a wide spectrum of disease severity. DESIGN AND
settingThe study was a pooled analysis of data from three multicenter clinical trials of cinacalcet in PHPT. PATIENTS: Patients were grouped into three disease categories for analysis based on the following: 1) history of failed parathyroidectomy (n = 29); 2) meeting one or more criteria for parathyroidectomy but without prior surgery (n = 37); and 3) mild asymptomatic PHPT without meeting criteria for either above category (n = 15).
interventionThe intervention in this study was treatment with cinacalcet for up to 4.5 yr. OUTCOMES: Measurements in the study included serum Ca, PTH, phosphate, and bone-specific alkaline phosphatase, and areal bone mineral density (aBMD). Vital signs, safety biochemical and hematological indices, and adverse events were monitored throughout the study period.
resultsThe extent of cinacalcet-induced serum Ca reduction, proportion of patients achieving normal serum Ca (≤10.3 mg/dl), reduction in serum PTH, and increase in serum phosphate were similar across all three categories. Except for decreased aBMD at the total femur indicated for parathyroidectomy group at 1 yr, no significant changes in aBMD occurred. The efficacy of cinacalcet was maintained for up to 4.5 yr of follow-up. AEs were mild and similar across the three categories.
conclusionsCinacalcet is equally effective in the medical management of PHPT patients across a broad spectrum of disease severity, and overall cinacalcet is well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.